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R E V I E W
The Impact of Prostate Cancer Treatment on 
Quality of Life: A Narrative Review with a Focus 
on Randomized Data
This article was published in the following Dove Press journal: 
Research and Reports in Urology
James M Taylor 
Victor E Chen 
Ryan C Miller 
Benjamin A Greenberger
Department of Radiation Oncology, 
Sidney Kimmel Medical College & Cancer 
Center at Thomas Jefferson University, 
Philadelphia, PA, USA 
Abstract: Despite excellent oncologic outcomes, the management of localized prostate 
cancer remains complex and is dependent on multiple factors, including patient life expec-
tancy, medical comorbidities, tumor characteristics, and genetic risk factors. Decades of 
iterative clinical trials have improved the optimization and utilization of surgical and radia-
tion-based modalities, as well as their combinatorial use with anti-androgen and systemic 
therapies. While cure rates are high and converging on equivalent disease control should an 
upfront surgical or radiotherapeutic approach be optimized, the long-term side effects of 
surgical and radiation-based treatments can differ significantly in nature. Decisions regarding 
the selection of therapy are therefore best made in an informed and shared medical decision- 
making process between clinician and patient with respect to cancer control as well as 
adverse effects. We outline in this narrative review an understanding regarding implications 
of surgical and radiation treatment on quality of life after treatment, and how these data may 
be considered in the context of advising patients regarding the selection of therapy. This 
narrative review largely focuses on the quality of life data obtained from prospective 
randomized trials of men treated for prostate cancer. We believe this provides the best 
assessment of the quality of life and can be used to inform patients when making treatment 
decisions. 
Keywords: prostate cancer, radical prostatectomy, radiation therapy, quality of life, toxicity
Approaches for Clinically Localized Prostate Cancer
Estimated 191,930 new cases of prostate cancer will be diagnosed in the United 
States in 2020, accounting for 21% of new cancer cases in men.1 Overall prognosis, 
especially in the setting of localized disease, is extremely good with five-year 
relative survival greater than 98% for all races between 2009 and 2015. In general, 
men who are older and have very low-risk prostate cancer may not benefit from 
active intervention and instead may choose a strategy of watchful waiting2 
(Table 1). For men who have longer life expectancy and low-risk disease, active 
surveillance, radical prostatectomy (RP), external beam radiation (XRT), and bra-
chytherapy (BT) are all options supported by the National Comprehensive Cancer 
Network (NCCN) guidelines.3–7 With regard to the radiation treatment course, 
conventional fractionation, hypofractionation, and stereotactic body radiotherapy 
(SBRT) may all be considered options based upon individual risk assessment, as 
well as tumor and treatment characteristics.8–12 NCCN favorable intermediate-risk 
disease (<50% of cores positive, no Gleason Grade Group 3 or higher histology, 
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only one intermediate-risk factor) has a treatment algo-
rithm that is similar to low-risk disease.13 Unfavorable 
intermediate-risk and high-risk diseases typically require 
the addition of androgen deprivation therapy (ADT), as 
well as potentially a brachytherapy boost, to external beam 
radiotherapy.6,14–20 Regarding length of ADT, unfavorable 
intermediate-risk disease and high-risk disease typically 
require 4–6 months and 18–36 months, respectively, with 
currently less level 1 data regarding justifying the optimal 
length of ADT in the setting of brachytherapy boost.6,21–25 
The addition of systemic therapy, e.g. docetaxel, to radia-
tion has been historically more controversial and indivi-
dualized in the context of high-risk, localized disease, 
though recent data from the GETUG 12 trial as well as 
RTOG 0521 have suggested superior 8-year relapse-free 
survival and 4-year overall survival, respectively.26,27 
Given the limited data, however, the addition of docetaxel 
to ADT plus XRT in high- or very high-risk prostate 
cancer is not categorically recommended as of NCCN 
Version 2.2020 until longer follow-up demonstrates com-
parable success of salvage treatments and rates of long- 
term adverse effects.
External beam radiation often incorporates pelvic nodal 
treatment when there is a threshold risk of lymph node 
involvement, e.g. 15% or higher28,29 (Figure 1). This risk 
is estimated based on clinical factors such as Gleason 
Score (GS) and Prostate Specific Antigen (PSA), often 
with the assistance of a nomogram. RTOG 0924 trial is 
underway to provide further insight into the definitive RT 
setting. Postoperatively, XRT and ADT still may be a 
requirement in the adjuvant setting depending on factors 
such as lymph node involvement, positive margins, extra-
prostatic extension, and seminal vesicle involvement.30–34 
If adjuvant treatment is not pursued based on favorable 
pathology, salvage radiation to the disease bed or pelvis, as 
well as ADT, still is required if there is clinical or bio-
chemical evidence of failure,35,36 with the extent of nodal 
treatment additionally under investigation in the salvage 
setting.37
The first generation of meta-analyses utilizing obser-
vational data compared surgical and radiation-based 
modalities across all risk groups of localized disease 
with regard to overall mortality (OM) and prostate can-
cer-specific mortality (PCM) hazard ratios, the most well 
known of which found OM and PCM benefits to upfront 
surgery across all groups.38 Additional efforts found that 
controlling for quality of ADT, adequate radiation dose, 
and overall compliance with modern NCCN standard-of- 
care diminished these differences.39,40 There is even a 
suggestion of improved PCM for RT-based modalities 
compared with RP in the setting of Gleason 9–10 disease 
when BT is used with XRT, though there are limited 
observational data available to answer this question.41– 
44 There is some evidence that this advantage for bra-
chytherapy boost diminishes in the setting of RP plus 
adjuvant RT.43,44 Should these data prove verifiable 
Table 1 Treatment Selection for Localized Prostate Cancer, Stratified by Risk Group
Disease Group Treatment Modalities
Low-Risk If expected patient survival ≥ 10 years, active surveillance, external beam radiation (standard fractionation, 




If expected patient survival ≥ 10 years, active surveillance, external beam radiation, brachytherapy, and radical 
prostatectomy are all options; if < 10 years, observation, external beam radiation, or brachytherapy is recommended
Unfavorable 
Intermediate-Risk
If expected patient survival ≥ 10 years, radical prostatectomy, external beam radiation with 4–6 months of ADT, 
external beam radiation and brachytherapy boost and 4–6 months of ADT are all options; if < 10 years, observation, 
external beam radiation with 4–6 months ADT, and external beam radiotherapy and brachytherapy boost and 4–6 
months ADT are all options
High-Risk If > 5 years or symptomatic, external beam radiation with 18–36 months ADT, external beam radiation and 
brachytherapy boost and 18–36 months of ADT, and radical prostatectomy are all options; if ≤ 5 years and 
asymptomatic, observation, external beam radiation and ADT are all options
Adjuvant/Salvage If adverse features (positive margins, seminal vesicle involvement, and/or extraprostatic extension), consider adjuvant 
external beam radiation; otherwise, close monitoring with external beam radiation and 6–24 months of ADT 
recommended if clinical or biochemical evidence of failure
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with prospective data, there may be a subset of patients 
with Gleason 9–10 or other high-risk diseases for which a 
discussion of treatment options may converge on XRT 
+BT with ADT versus RP with a very strong possibility 
of requiring adjuvant RT. Counseling patients regarding 
the burden of GU-related toxicity associated with BT- 
boost is substantially different if the pre-procedural prob-
ability is high that adverse features will prompt adjuvant 
radiation to the prostatic fossa and possibility pelvic 
lymph nodes.
Given the high rates of success for oncologic out-
comes as well as more robust algorithms to achieve 
similar oncologic outcomes with upfront RP or RT, 
there is a need to better understand the toxicities of 
various treatment modalities and how they affect patient 
quality of life. To help providers with this important 
conversation, we have provided a narrative review of 
the data involving treatment-related toxicity and poten-




Figure 1 Surgical and Radiotherapeutic Approaches in the Treatment of Prostate Cancer. (A) pre- and post-prostatectomy anatomy with retropubic and perineal surgical 
approaches. (B) microsurgical anatomy at risk for injury with retropubic and surgical approaches. (C) clinical target volumes (CTV) for radiotherapy for intact prostate 
treated definitively with external beam radiotherapy (XRT). When indicated pelvic lymph node fields are added, increasing the potential for gastrointestinal toxicity. (D) CTV 
for radiotherapy for prostate fossa treated adjuvantly or in salvage cases. The utility of lymph node coverage in this setting is the subject of clinical investigation. (E) CTV for 
low-dose-rate brachytherapy with or without XRT treatment. High-dose-rate techniques are available using temporary catheter-based placement of an Ir-192 source with 
established fractionation schedules and fewer post-treatment radiation precautions.
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Methods
We performed a search of the PubMed database to identify 
pertinent articles that included quality of life assessments 
relating to the treatment of prostate cancer and common 
treatment modalities including RP, XRT, BT, and ADT. 
The search focused on randomized clinical trials compar-
ing treatment modalities for prostate cancer that included 
quality of life metrics. In addition to database searches, 
hand searches were also conducted based on expert opi-
nion and author consensus. Studies including intraopera-
tive fresh-frozen pathologic analysis of margins to 
improve nerve sparing during RP or injection of hydrogel 
spacers to improve rectal sparing during RT were not 
included, given their relative novelty and lack of rando-
mized data comparing surgical and radiotherapeutic out-
comes. Searches of published abstracts were also included 
in the formation of the manuscript when full articles were 
not available. Finally, the manuscript and reference list 
were evaluated and approved by all authors for inclusion 
in the current publication.
Technical Approaches for Surgery 
and Radiation
In general, there are two common approaches to RP, one 
which employs a retropubic approach, in which the pros-
tate is removed through an incision in the wall of the 
abdomen, and the other a perineal approach, in which the 
incision is made in the area between the scrotum and 
anus45 (Figure 1). Retropubic prostatectomy was consid-
ered the gold standard since the early 1980s due to the 
ability to access and remove pelvic lymph nodes, as well 
as spare cavernosal nerves. The dorsal vein complex is at 
risk, however, and blood loss requiring transfusions has 
been shown to be a risk of this approach.46 Since many 
patients at low risk for metastasis do not require extensive 
pelvic lymph node dissection, a perineal prostatectomy is 
an alternative approach and often causes less blood loss by 
avoiding the dorsal vein complex.47 Regarding robotic 
prostatectomy, studies have shown lower estimated blood 
loss, shorter hospital stays, a lower incidence of bladder 
neck contractures/anastomotic strictures, and lower intrao-
perative adverse event.48 However, there is a lack of 
randomized, long-term studies that compare functional 
and oncologic outcomes between open and robotic 
approaches. Modern robotic techniques (e.g., 
NeuroSAFE) continue to evolve, including intraoperative 
fresh-frozen section analysis of prostate margins to assess 
and optimize oncologic resection while maintaining func-
tional outcomes, with randomized trials underway.49 
Overall, most patients who opt for definitive management 
with prostatectomy can initially avoid androgen depriva-
tion therapy and its associated effects on quality of 
life (QOL).
With regard to radiation, there are multiple techniques 
including XRT and BT. Dose escalation to 74–81 Gy has 
been shown to improve biochemical failure-free survival 
over lower doses; however, no overall survival benefit has 
been shown with these increasing doses over lower doses 
(~70 Gy).8,50–53 Hypofractionation, which typically uses 
60–70 Gy over a shorter time interval, has demonstrated 
noninferiority to standard fractionation for low, intermedi-
ate, and high-risk disease; SBRT, a form of ultra-hypo-
fractionated RT using image guidance and highly 
conformal techniques, has appeared safe at currently avail-
able follow-up and has allowed select patients to finish 
radiotherapy in 2 weeks.54 Treatment to the prostate in the 
definitive setting is delivered to the organ with an addi-
tional 5–10 mm margin to account for organ motion or 
setup uncertainties, with the extent of coverage of the 
seminal vesicles informed by risk group and several inten-
sity-modulated radiotherapy protocols available to guide 
planning.55 Surrounding organs, such as the bladder, rec-
tum, penile bulb, and bilateral femora, are delineated dur-
ing planning as they receive radiation dose during 
treatment.56 In the adjuvant and salvage setting, the pros-
tate fossa is typically defined as at least 2 cm above the 
pubic symphysis to the top of the penile bulb, including 
surgical clips and seminal vesicle remnants if involvement 
is detected, with an additional 8–15 mm margin added due 
to setup uncertainty and movement.57 The decision to treat 
lymph nodes significantly affects the anticipated exposure 
to the rectum and surrounding organs, as does the amount 
of margin necessary in the setting of chosen technique and 
image guidance. Rectal spacers are often used to mitigate 
short and late-term side effects of radiation therapy,58 
though these techniques have not yet been reflected in 
randomized data comparing the quality of life following 
surgery versus radiation.
Limited Conclusions from 
Retrospective Observational Data
The reference standard in determining the impact any 
treatment modality has on an individual patient is the use 
of patient-reported outcomes (PROs), as they represent the 
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patients’ perspective on how their quality of life has chan-
ged in contrast to physician-graded toxicity.59 Reportable 
tools and assessments have been developed and increas-
ingly deployed across observational and prospective 
research.60 Given the sample sizes and amount of follow- 
up required to measure differences in both frequent and 
infrequent morbidity endpoints, it has been tempting to use 
prostate cancer registries to answer questions regarding the 
differential incidence of various toxicities between 
approaches using upfront RP and RT. These cancer regis-
tries have tracked different levels of detail concerning 
treatment, with several important features such as ADT 
use, RT dose, and radiation technique inconsistently 
tracked and reported.61 Moreover, the use of these regis-
tries has more categorially been challenged by data sug-
gesting that the systematic concordance between hazard 
ratios generated from observational studies and corre-
sponding randomized controlled trials is little better than 
if left to chance.62
Despite these caveats, multiple efforts have attempted 
to leverage large sample size and registry data to answer 
quality of life questions following prostate cancer 
treatment.63–66 The Prostate Cancer Outcomes Study uti-
lized six Surveillance, Epidemiology and End Results 
registries to recruit 3533 men, 1655 of whom had surgery 
or radiotherapy for localized disease within a year of 
diagnosis with follow-up surveys at 2 and 5 years.63 Men 
following surgery demonstrated more urinary incontinence 
and erectile dysfunction, while those receiving radiother-
apy predominantly demonstrated GI symptoms including 
bowel urgency. These symptoms were noted at the early 
time points of 2 and 5 years, though all differences save 
for bowel symptoms were insignificant by year 15. Most 
of these men notably received an older generation of 
radiation therapy, with inconsistent utilization of ADT, 
though more modern data have been utilized to replicate 
these findings.64,65
Quality of Life Outcomes from 
Randomized Data and Prospective 
Cohort Studies
Prospective randomized controlled trials (PRTs) are con-
sidered by many as the reference standard for clinical 
studies as they allow for equal distribution of both mea-
sured and unmeasured covariates across strata of control 
and exposure groups, create a baseline timepoint for 
cohort evaluation and lend to easy statistical analysis. It 
has become increasingly important to also assess func-
tional outcomes when designing and conducting clinical 
trials in men with prostate cancer due to the improved 
understanding of converging oncologic outcomes with 
surgery and radiation. Accordingly, it would reason that 
PROs incorporated into prospective randomized studies of 
men treated for prostate cancer would serve as the highest 
level of evidence to directly compare treatment-related 
toxicity and QOL. Despite this, there remains a paucity 
of PROs obtained from RCT’s to help guide physicians 
and patients on expected toxicities when selecting an 
appropriate treatment approach in the setting of multidis-
ciplinary care.
The quality of life companion article of men enrolled 
in the Prostate Testing for Cancer and Treatment (ProtecT) 
trial may provide the best prospective QOL data in men 
with localized prostate cancer following treatment with 
one of the most commonly used methods: surgery, radio-
therapy or active monitoring.67 Briefly, the ProtecT study 
was a multicenter, randomized clinical trial of men with 
screening-detected prostate cancer who were randomized 
in a 1:1:1 fashion to either radical prostatectomy, active 
monitoring or radiotherapy with 4 months of ADT.4 In all, 
545 men were randomized to active monitoring, 553 men 
to radical prostatectomy and 545 men to radiotherapy + 
ADT. After 10 years of follow-up, the authors noted no 
difference in PCM, though the measured PCM remained 
low in all cohorts, with only 17 prostate cancer-specific 
deaths.4 It is important to note that most men enrolled in 
the ProtecT study had low-risk disease and further extra-
polation of this study to cohorts of men with high-risk 
disease is cautioned, a risk category that will likely need to 
wait for the results of SPCG-15 for randomized data.68
In the ProtecT QOL study by Donovan et al, 1643 men 
enrolled on ProtecT completed validated questionnaires 
before diagnosis, at 6 and 12 months after randomization, 
and annually thereafter.67 The companion study was 
designed to provide a direct comparison of the QOL of 
men treated uniformly with either radiotherapy/ADT, radi-
cal prostatectomy, or active monitoring. The study 
included validated measures that assessed multiple 
domains including urinary, bowel, sexual function, and 
specific effects on quality of life, anxiety, depression and 
general health. The published report included 5 years of 
follow-up data on cancer-related quality of life and 6 years 
of follow-up data on additional endpoints. The authors 
analyzed the data according to the intention-to-treat prin-
ciple based upon patient randomization into the treatment 
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groups of the ProtecT trial. Overall, radical prostatectomy 
was associated with worse outcomes in erectile dysfunc-
tion and urinary incontinence compared with radiotherapy 
and 4 months of ADT. Conversely, radiotherapy and ADT 
were associated with significantly more bowel toxicity 
(Table 2). Importantly, when assessing the entire cohort, 
no significant differences were observed among any treat-
ment group in general health-related, cancer-related qual-
ity of life, depression or anxiety.67 Despite equivalence in 
global health-related quality of life between treatment 
modalities, the study does demonstrate that toxicity pro-
files between radiotherapy and radical prostatectomy are 
different. These data are useful when discussing with 
patients. Overall, radiotherapy is more associated with 
worsened bowel symptoms while prostatectomy is asso-
ciated with worsening of urinary incontinence and erectile 
dysfunction. To magnify this association, the authors 
report that compared to the active monitoring group the 
number needed to treat (NNT) to cause a single additional 
case of erectile dysfunction at 2 years is 4 with radical 
prostatectomy and 8 with radiotherapy, and the NNT to 
cause a single additional case of urinary incontinence at 2 
years is 5 for RP and 143 for RT. However, as follow-up 
continued to 6 years the authors demonstrate that urinary 
and sexual function had stabilized in the radiotherapy 
group after improving for 2–3 years, while urinary and 
sexual function declined over this time period in the active 
monitoring group. As such, with this additional follow-up, 
the authors conclude that men treated with either active 
monitoring or radiotherapy with ADT had similar QOL 
with respect to sexual function and urinary incontinence, 
but these scores remained worse in men treated with 
prostatectomy.
It is important to note that the ProtecT study used 
modern approaches to surgery and thus may not be biased 
by older surgical procedures. The authors note that the 
majority of the 545 men randomized to radical prostatect-
omy underwent an open retropubic, nerve-sparing proce-
dure. This nerve-sparing approach would be expected to 
reduce the rates of toxicities such as erectile dysfunction. 
In the radiation arm, patients were treated with modern 
dose-escalated prescriptions to 7400 cGy in 37 fractions 
using three-dimensional conformal radiotherapy. While the 
dose in this cohort reflects modern prescribing, newer 
techniques such as intensity-modulated radiotherapy 
(IMRT) or volumetric modulated arc therapy (VMAT) 
are now more routinely used as they are associated with 
fewer toxicities compared with 3D conformal radiation.69 
Despite this, the QOL data from the ProtecT study provide 
high-quality evidence regarding the impact of modern 
treatments for men with clinically localized prostate can-
cer and can be used to guide physicians and patients when 
considering treatment recommendations.
Another PRT comparing surgery vs radiotherapy with 
PROs was conducted by Lennernas et al and included men 
with locally advanced high-risk prostate cancer.70 This 
study conducted in Sweden between 1996 and 2001 
included 89 men and randomized them 1:1 to either radical 
prostatectomy or radiotherapy consisting of 50 Gy external 
beam radiotherapy with high-dose-rate brachytherapy 
delivered in 2 separate fractions of 10 Gy each. All men 
in the trial were also treated with 6 months of neoadjuvant 
total androgen blockade. The primary outcome was the 
difference in health-related quality of life (HRQoL) using 
PROs. The study assessed self-reported HRQoL and 
symptoms including urinary, bowel, and sexual function 
prior to randomization and at 12 and 24 months following 
randomization.70 The authors report that no discernible 
differences in HRQoL or complications were demon-
strated between the two treatment groups. One unique 
aspect of the study is that all men were treated with total 
androgen blockade. This allows for a better comparison 
between the two treatment modalities of radiotherapy and 
surgery without ADT confounding the radiotherapy arm. It 
also compares what has been described as maximal radio-
therapy with combination XRT and BT. Combination XRT 
and BT have been shown to be associated with signifi-
cantly more toxicity compared with XRT alone in prospec-
tive studies.20 Given that all men were treated with ADT 
and the radiotherapy arm received maximal radiotherapy, 
this study provides data that even in high-risk men treated 
aggressively, HRQoL as measured using PROs was similar 
between treatment arms. This study is limited by the small 
sample size and the nonconventional XRT dose given in 
the radiation arm but still provides valuable information 
using PROs from an RCT.
Another (pseudo)randomized study that published 
PROs is the American College of Surgeons Oncology 
Group Phase III Surgical Prostatectomy versus Interstitial 
Radiation Intervention Trial (ACOSOG SPIRIT) by Crook 
et al.71 This study compared RP with BT given definitively 
as monotherapy. The trial was initially designed as a 
randomized study but after slow accrual, the protocol 
was amended to allow patients to choose or be randomized 
to either RP or BT. Overall, the trial was terminated early 
due to poor accrual but the authors report on HRQoL at 5 
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years in patients enrolled on the trial. Overall, 168 men 
were eligible for the toxicity analysis. In the entire cohort, 
60.7% of men had BT (9.5% randomly assigned) and 
39.3% of men had an RP (9.5% randomly assigned). 
Five years after treatment all men were considered for 
HRQoL evaluation using the cancer-specific 50-item 
Expanded Prostate Cancer Index Composite, the Short 
Form 12 Physical Component Score, and the Short Form 
12 Mental Component Score. The overall response rate 
was 88.4%. With a median follow-up of 5.2 years, the 
authors report no differences between RP and BT in bowel 
or hormonal domains. However, men treated with BT 
scored better in urinary (91.8 v 88.1; p= 0.02) and sexual 
(52.5 v 39.2; p= 0.001) domains as well as in patient 
satisfaction (93.6 v 76.9; P <0.001).71 This study is limited 
in its small sample size and largely non-random allocation 
(only 19% of patients were randomly assigned) but pro-
vides evidence that brachytherapy as monotherapy had 
fewer adverse effects on HRQoL compared with 
prostatectomy.
In a similar study, Giberti et al randomized 200 patients 
to either radical retropubic prostatectomy or brachytherapy 
as monotherapy and reported on oncological and func-
tional outcomes.72 Men randomized to surgery underwent 
bilateral nerve-sparing retropubic RP and standard lymph 
node dissection and men randomized to BT received low- 
dose rate brachytherapy using I-125 seeds with a pre-
scribed dose of D90 > 140 Gy. All men received ques-
tionnaires including the International Prostate Symptom 
Score (IPSS), International Index of Erectile Function 
(IIEF), and the EORTC-QLQ-C30/PR25. Patients enrolled 
in the study completed questionnaires before treatment as 
well as every 3 months for the first year, every 6 months 
for the second year, and then annually. In this study, the 
authors report that RP was associated with worse erectile 
function while BT was associated with worse urinary 
voiding symptoms and bowel symptoms. Unlike the pre-
viously discussed studies, the authors found no difference 
in rates of urinary incontinence between study arms. 
Finally, as demonstrated in several other PRTs with 
PROs the authors report equivalent HRQoL between the 
treatment arms.72
Although not a trial of radiation compared with pros-
tatectomy, the Androgen Suppression Combined with 
Elective Nodal and Dose Escalated Radiation Therapy 
(ASCENDE-RT) trial was a PRT of men with localized 
prostate cancer randomized to two different radiation 
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received 12 months of neoadjuvant ADT followed by XRT 
to the prostate and elective nodes to a total dose of 46 Gy. 
Men were randomized into one of the two radiation boost 
arms: a standard dose-escalated XRT boost of an addi-
tional 32 Gy to a total of 78 Gy, or an LDR brachytherapy 
implant. The authors conclude that with 9 years of follow- 
up patients treated with an LDR brachytherapy implant 
had improved biochemical progression-free survival. 
However, compared with men who only received an 
XRT boost, those who underwent LDR brachytherapy 
had worse GU and GI toxicity as graded using the mod-
ified Late Effects of Normal Tissue – Somatic, Objective, 
Management, Analytic (LENT-SOMA) scale.73 Although 
not an RCT between surgery and radiotherapy this study 
provides evidence that XRT with ADT combined with an 
LDR brachytherapy procedure has greater toxicity com-
pared with the more commonly used approach of ADT 
with dose-escalated external beam radiotherapy.
A recently published prospective cohort study by 
Hoffman et al detailed the QOL impact of 1386 men 
with favorable-risk localized prostate cancer treated with 
either active surveillance (n=363), nerve-sparing prosta-
tectomy (n=675), XRT alone (n=261) or low-dose rate 
brachytherapy (n=87) and in men with unfavorable-risk 
localized prostate cancer treated with RP (n=402) or 
XRT + ADT (n=217).74 Patients reported their function 
using the 26-item Expanded Prostate Index Composite 5 
years after completing treatment. Among men with favor-
able-risk disease, nerve-sparing prostatectomy was asso-
ciated with worse urinary continence at 5 years and sexual 
function at 3 years compared with active surveillance. 
XRT was not associated with worse bowel, urinary or 
sexual side effects compared with active surveillance at 
any point during 5 years after treatment. In the unfavorable 
risk subset, XRT + ADT was associated with worse bowel 
function at 1 year, but better sexual function and incon-
tinence compared with RP at each time point through 5 
years. Overall, the results of the Hoffman analysis provide 
evidence that XRT has a more favorable toxicity profile 
compared with RP even when ADT is added in the unfa-
vorable subgroup. Fortunately, none of the treatment 
groups reported meaningful declines in the HRQOL 
domains of physical function, emotional well-being, and 
energy/fatigue scores.
As discussed, ADT is often added to XRT or BT in 
unfavorable intermediate-risk and high-risk patient popu-
lations. In addition to the toxicities caused by radiotherapy, 
ADT introduces additional side effects. Several studies 
have shown that ADT independent of the effects of radio-
therapy contributes to worse sexual function.75,76 In a 
study by Gay et al the addition of neoadjuvant ADT to 
XRT or BT was associated with worse QOL. Specifically, 
the authors demonstrate that men on ADT had a decreased 
ability to reach orgasm, had decreased quality of erections 
and decreased sexual function.77 ADT also has metabolic 
effects and can lead to increased weight gain and loss of 
muscle mass. Unlike other toxicities associated with pros-
tate cancer treatment, the side effects attributable to ADT 
are often only transient and resolve after discontinuation 
and normalization of testosterone levels.
Finally, in men who undergo RP but require post- 
operative radiotherapy either in the adjuvant or salvage 
setting the addition of radiotherapy after prostatectomy has 
been shown to worsen QOL. Jenkins et al studied 106 men 
with PCa receiving post-prostatectomy radiotherapy and 
assessed the QOL impact of radiotherapy using the 
Expanded Prostate Cancer Index Composite (EPIC). The 
authors demonstrate that post-prostatectomy radiotherapy 
worsened urinary QOL with the most significant decline 
noted in urinary incontinence.78 Other studies of post- 
prostatectomy radiotherapy show only temporary worsen-
ing of symptoms in urinary, sexual and bowel domains.79 
Overall, studies seem to indicate a worse urinary function 
in men who require post-prostatectomy radiotherapy.80 
Given this information, it is important to consider these 
implications when counseling men with high risk, high 
volume disease (Gleason score 9–10) who would most 
likely require adjuvant/salvage radiotherapy following 
RP. In this setting, men may wish to consider definitive 
XRT + ADT and forgo RP given the high chances of 
requiring additional radiotherapy and the negative QOL 
impacts demonstrated in men receiving both modalities of 
treatment.
Managing Toxicities Associated with 
Prostate Cancer Treatments
Given how successful treatment generally is for localized 
prostate cancer, managing the adverse effects associated 
with the various available treatment strategies is of para-
mount importance in order to maximize patient quality-of- 
life. For example, it is well known that one of the most 
bothersome toxicities associated with a surgical approach 
to prostate cancer treatment is urinary incontinence, with 
the risk of incontinence being highly dependent on both 
age and surgical technique.81 Multiple strategies to aid 
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men to recover urinary control have been investigated, 
including both procedural and non-procedural techniques. 
For example, placement of artificial urinary sphincters has 
been shown to be a viable option, with the caveat that late 
complications may occur which may require further pro-
cedural intervention to remove the device.82 In addition, 
transobturator sling suspension via placement of transob-
turator tape has also been studied, resulting in a significant 
rate of both complete cure of incontinence and decreased 
pad usage.83 Finally, behavioral training with biofeedback 
seems to be effective specifically for stress and urge 
incontinence, but less so with patients who experience 
continual leakage of urine following a prostatectomy.84
While incontinence following radiation treatment for 
prostate cancer is a rare side effect, radiation may instead 
cause hemorrhagic cystitis and radiation proctitis, both of 
which also negatively impact patient quality of life. 
Radiation cystitis can manifest itself both in the acute 
post-treatment time period and multiple months to years 
following completion of radiation treatment, and can vary 
significantly in severity from a mild bleed up to significant 
hemorrhage; as such, management strategies differ but 
include cystoscopy with electrocoagulation of bleeding 
areas, injection of botulinum toxin into the bladder wall, 
and instillation of compounds such as formalin or prosta-
glandins into the bladder itself.85 For radiation proctitis, 
direct instillation of formalin during a sigmoidoscopy has 
shown to be effective and often results in immediate 
resolution of symptoms.86,87 Alternatively, argon plasma 
coagulation, also performed during a flexible sigmoido-
scopy, has also been demonstrated to be effective in both 
reducing blood transfusion requirements related to radia-
tion proctitis and improving other aspects of bowel func-
tion such as resolving rectal urgency and stool 
frequency.88 Radiofrequency ablation is an option for 
those whose symptoms do not resolve with first or sec-
ond-line interventions as well.89 For those who prefer a 
less invasive therapy, short-chain fatty acid enemas were 
superior to placebo in a prospective, randomized double- 
blind trial examining the rapidity of healing of radiation 
proctitis.90 Finally, hyperbaric oxygen has been shown to 
be an effective treatment strategy for both patient com-
plaints of hematuria related to radiation cystitis and rectal 
bleeding or irritation from radiation proctitis following 
radiation treatment for prostate cancer, but the use of this 
technique is generally reserved after other lines of therapy 
have been ineffective.91,92
For many men undergoing treatment for prostate cancer, 
maintenance of sexual function is an extremely important 
consideration and component of their quality of life; unfor-
tunately, sexual dysfunction is a common adverse effect of 
both RT and RP, with similar rates for both therapies (parti-
cularly now that surgical techniques have improved such 
that nerve-sparing approaches are possible for localized 
disease). Complicating studies on this subject is the fact 
that with the exception of a recently validated standardized 
questionnaire, the International Index of Erectile Function 
(IIEF), defining terms such as “potency,” “satisfactory sex-
ual function,” “sexual interest,” and “libido,” among others, 
is dependent on individual interpretation.93 The first-line 
treatment for erectile dysfunction is generally an oral phos-
phodiesterase type 5 (PDE5) inhibitor, although specific 
dosages and frequencies of administration vary.94 In fact, 
prophylactic sildenafil citrate initiated before radiation ther-
apy for prostate cancer and given continuously with the 
intent of preserving erectile function until 6 months follow-
ing completion of radiation therapy was demonstrated to 
improve long-term sexual outcomes.95 Should patients not 
respond to oral PDE5 agents, patients are generally offered 
penile injections, penile implants, or vacuum erection 
devices.96–98 Less invasive options such as exercise therapy 
(with moderate to high intensity aerobic and resistance 
training exercises) have also been shown to be effective, 
even though they do not directly act on sexual organs, as 
sexual function is intimately interwoven with mental health 
and well-being.99 Finally, clear, constructive communica-
tion between patients and their partners has been consis-
tently shown to be one of the most important factors in 
helping patients cope with sexual problems following pros-
tate cancer treatment.100
Perhaps most importantly, comprehensive patient counsel-
ing of the risks and benefits of each potential treatment option 
is appropriate in men with localized prostate cancer. Many 
tools are available to aid this process; for example, nomograms 
have been developed to predict both acute and long-term rectal 
toxicity associated with radiation therapy101–103 as well as 
urinary adverse events.104 Involvement of a multidisciplinary 
team of healthcare providers is essential such that the patient is 
able to appreciate all available options for treatment, and 
ultimately, although a consensus recommendation can be 
made based on patient characteristics and/or disease involve-
ment, patient participation with an informed final decision is 
the most critical component to the management of patient 
expectations regarding toxicity.105–107
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Conclusion
As discussed, there is a paucity of prospective randomized 
data with PRO metrics for men treated with localized 
prostate cancer. Based on the current review it appears 
that prostatectomy is associated with higher rates of urin-
ary incontinence and erectile dysfunction compared to 
radiotherapy. Unlike surgery, radiotherapy appears to be 
associated with worsening bowel function. However, 
despite these differences, prospective evaluation seems to 
indicate that global HRQoL does not differ in men by 
treatment modality. Thus, an individualized discussion 
that compares and contrasts different toxicity profiles of 
each treatment modality may be the best approach clini-
cally to encourage patient engagement in the shared med-
ical decision-making process. There are myriad tools and 
interventions, both procedural and non-procedural, avail-
able to address the sequelae of an upfront RP or RT-based 
approach. In the future, we believe that all men with 
prostate cancer should have an informed discussion in 
the setting of a multi-disciplinary setting to hear of all of 
the information available before deciding on a treatment 
approach.
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